Safety and efficacy of first-generation and second-generation drug-eluting stents in the setting of acute coronary syndromes.

Abstract

Drug-eluting stents (DESs) are known to reduce in-stent restenosis rate, compared with bare metal stents (BMSs). Stent thrombosis, one of the most dangerous complications of DES, has emerged as a major concern. This issue has limited the use of DES in unstable coronary artery disease till recent years. In fact, acute coronary syndrome (ACS) and the subsequent activation of the hemocoagulative pathway could represent a prothrombotic environment, thus limiting the use of DES in this situation. Nowadays, there is increasing evidence in literature of similar stent thrombosis rates both for BMS and DES in ACS, and most interventional cardiologists are confident with the use of DES in ACS. The aim of this article is to review the current literature on this topic in order to compare first-generation and second-generation DES vs. BMS as concerns safety and efficacy.

• Authors: Riccardo Gorla, Marco Loffi, Edoardo Verna, Alberto Margonato, Jorge Salerno-Uriarte
• Journal: Journal of cardiovascular medicine (Hagerstown, Md.) (J Cardiovasc Med (Hagerstown)) Vol. 15 Issue 7 Pg. 532-42 (Jul 2014) ISSN: 1558-2035 [Electronic] United States
• PMID: 24922044 (Publication Type: Journal Article, Review)

Topics

• Acute Coronary Syndrome (surgery)
• Coronary Restenosis (prevention & control)
• Drug-Eluting Stents
• Humans
• Percutaneous Coronary Intervention (methods)
• Postoperative Complications (prevention & control)
• Prosthesis Design
• Treatment Outcome